CN115768749A - 二甲基亚磺酰亚胺衍生物 - Google Patents

二甲基亚磺酰亚胺衍生物 Download PDF

Info

Publication number
CN115768749A
CN115768749A CN202180041378.4A CN202180041378A CN115768749A CN 115768749 A CN115768749 A CN 115768749A CN 202180041378 A CN202180041378 A CN 202180041378A CN 115768749 A CN115768749 A CN 115768749A
Authority
CN
China
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
reaction
ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202180041378.4A
Other languages
English (en)
Other versions
CN115768749B (zh
Inventor
钱文远
廖勇刚
韦昌青
奚正英
肖瑶
陈曙辉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cisen Pharmaceutical Co ltd
Original Assignee
Medshine Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medshine Discovery Inc filed Critical Medshine Discovery Inc
Publication of CN115768749A publication Critical patent/CN115768749A/zh
Application granted granted Critical
Publication of CN115768749B publication Critical patent/CN115768749B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/34—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/54—Nitrogen and either oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/36—Nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

本发明公开了一系列二甲基亚磺酰亚胺衍生物，具体公开了式(IΙ)所示化合物及其药学上可接受的盐。
Figure DDA0003988397190000011

Description

PCT国内申请，说明书已公开。

Claims (20)

  1. PCT国内申请，权利要求书已公开。
CN202180041378.4A 2020-06-11 2021-06-07 二甲基亚磺酰亚胺衍生物 Active CN115768749B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN202010528855 2020-06-11
CN2020105288557 2020-06-11
CN202010779149X 2020-08-05
CN202010779149 2020-08-05
PCT/CN2021/098601 WO2021249337A1 (zh) 2020-06-11 2021-06-07 二甲基亚磺酰亚胺衍生物

Publications (2)

Publication Number Publication Date
CN115768749A true CN115768749A (zh) 2023-03-07
CN115768749B CN115768749B (zh) 2024-04-19

Family

ID=78845319

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180041378.4A Active CN115768749B (zh) 2020-06-11 2021-06-07 二甲基亚磺酰亚胺衍生物

Country Status (5)

Country Link
US (1) US20230219920A1 (zh)
EP (1) EP4166541A1 (zh)
JP (1) JP2023528968A (zh)
CN (1) CN115768749B (zh)
WO (1) WO2021249337A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023098613A1 (zh) * 2021-12-03 2023-06-08 南京明德新药研发有限公司 二甲基亚磺酰亚胺衍生物的制备方法
WO2023098612A1 (zh) * 2021-12-03 2023-06-08 南京明德新药研发有限公司 二甲基亚磺酰亚胺衍生物的盐型及晶型

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1245490A (zh) * 1997-01-29 2000-02-23 辉瑞大药厂 磺酰脲衍生物及其在白介素－1活性的控制中的用途
WO2017184604A1 (en) * 2016-04-18 2017-10-26 Ifm Therapeutics, Inc Compounds and compositions for treating conditions associated with nlrp activity
CN107428696A (zh) * 2015-02-16 2017-12-01 昆士兰大学 磺酰脲和相关化合物及其用途
CN111094243A (zh) * 2017-07-24 2020-05-01 诺华炎症研究公司 用于治疗与nlrp活性相关的病症的化合物和组合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3872070A1 (en) * 2016-04-18 2021-09-01 Novartis AG Compounds and compositions for treating conditions associated with nlrp activity
EP3272739A1 (en) 2016-07-20 2018-01-24 NodThera Limited Sulfonyl urea derivatives and their use in the control of interleukin-1 activity
GB201712282D0 (en) 2017-07-31 2017-09-13 Nodthera Ltd Selective inhibitors of NLRP3 inflammasome
GB201721185D0 (en) 2017-12-18 2018-01-31 Nodthera Ltd Sulphonyl urea derivatives

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1245490A (zh) * 1997-01-29 2000-02-23 辉瑞大药厂 磺酰脲衍生物及其在白介素－1活性的控制中的用途
CN107428696A (zh) * 2015-02-16 2017-12-01 昆士兰大学 磺酰脲和相关化合物及其用途
WO2017184604A1 (en) * 2016-04-18 2017-10-26 Ifm Therapeutics, Inc Compounds and compositions for treating conditions associated with nlrp activity
CN111094243A (zh) * 2017-07-24 2020-05-01 诺华炎症研究公司 用于治疗与nlrp活性相关的病症的化合物和组合物

Also Published As

Publication number Publication date
EP4166541A1 (en) 2023-04-19
CN115768749B (zh) 2024-04-19
WO2021249337A1 (zh) 2021-12-16
JP2023528968A (ja) 2023-07-06
US20230219920A1 (en) 2023-07-13

Similar Documents

Publication Publication Date Title
JP6650983B2 (ja) トロンビンの阻害剤としての多置換芳香族化合物
WO2021175199A1 (zh) 一类芳香杂环类化合物及其在药物中的应用
US20230143751A1 (en) Aromatic Compound And Use Thereof In Preparing Antineoplastic Drugs
JP4228398B2 (ja) 神経ペプチドｙ受容体拮抗剤
TWI324066B (en) A pharmaceutical composition for inhibiting cell migration induced by an angiogenic factor
TW202204323A (zh) 經取代之嗒𠯤化合物
JP2978850B2 (ja) ２−アミノベンズアゼピン誘導体
JP7061236B2 (ja) Ｍｔｏｒｃモジュレーターおよびその使用
JPH06508816A (ja) （ｓ）（＋）−２−エトキシ−４−［ｎ−［１−（２−ピペリジノ−フェニル）−３−メチル−１−ブチル〕アミノカルボニルメチル〕−安息香酸、この化合物を含む医薬組成物及びその調製方法
CN102112453A (zh) 新的钾通道阻断剂及其用途
CN115768749B (zh) 二甲基亚磺酰亚胺衍生物
JP2021527660A (ja) ＲＯＲγｔのモジュレータとしてのフェニル及びピリジニル置換イミダゾール
CN113993860A (zh) 作为kras g12c突变蛋白抑制剂的七元杂环类衍生物
JP2021522201A (ja) Ｒｈｏキナーゼ阻害剤としてのベンゾピラゾール系化合物
JP7028780B2 (ja) ベンズアミド誘導体
CN110423221A (zh) 作为凝血酶抑制剂的卤代吡唑
TW202302587A (zh) 異喹啉酮類化合物及其用途
WO2014127722A1 (zh) 氮杂环取代二氢青蒿素衍生物及其应用
KR101601999B1 (ko) 2-옥소-알킬-1-피페라진-2-온의 유도체, 그의 제조 방법 및 그의 치료 용도
WO2021129841A1 (zh) 用作ret激酶抑制剂的化合物及其应用
US8513420B2 (en) Amino-naphthyridine derivatives
JP2021525784A (ja) チエノ［２，３−ｃ］ピリダジン−４（１Ｈ）−オン系誘導体及びその使用
WO2022022646A1 (zh) 含硒五元杂芳环化合物
JPH10231285A (ja) フタルイミド誘導体又はその塩、それらの製造方法及びそれらを含有する医薬組成物
CN117343064B (zh) 一种具有抗病毒作用的嘧啶衍生物的制备与应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40089693

Country of ref document: HK

TA01 Transfer of patent application right

Effective date of registration: 20240307

Address after: Tongji Science and Technology Industrial Park, high tech Zone, Jining City, Shandong Province

Applicant after: CISEN PHARMACEUTICAL Co.,Ltd.

Country or region after: China

Address before: 210032 room 218, business office building, No.9 Gaoxin Road, Jiangbei new district, Nanjing City, Jiangsu Province

Applicant before: Nanjing Mingde New Drug Development Co.,Ltd.

Country or region before: China

TA01 Transfer of patent application right
GR01 Patent grant
GR01 Patent grant